November 30, 2016 - By Marguerite Chambers · 0 Comments
The stock of Contravir Pharmaceuticals Incorporated (NASDAQ:CTRV) registered an increase of 127.26% in short interest. CTRV’s total short interest was 3.19M shares in November as published by FINRA. Its up 127.26% from 1.41M shares, reported previously. With 5.08 million shares average volume, it will take short sellers 1 days to cover their CTRV’s short positions. The short interest to Contravir Pharmaceuticals Incorporated’s float is 6.6%. About 362,648 shares traded hands. ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has risen 98.10% since April 27, 2016 and is uptrending. It has outperformed by 92.87% the S&P500.
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $119.61 million. The Firm focuses on the development of antiviral drugs for the treatment of Hepatitis B virus infections. It currently has negative earnings. The Firm develops a range of compounds to treat HBV infection, which include CMX157 and CRV431.
ContraVir Pharmaceuticals, Inc., incorporated on May 15, 2013, is a biopharmaceutical company. The Firm focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Firm develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Firm is also developing an antiviral asset, FV-100.
More news for ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) were recently published by: Prnewswire.com, which released: “ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors” on September 21, 2016. Prnewswire.com‘s article titled: “ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer” and published on March 31, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers